OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board with Appointment of Nucleic Acid Therapeutics and Immunology Specialist Dr. Gunther Hartmann

Suwon, Republic of Korea, November 30, 2021 – OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the appointment of Dr. Gunther Hartmann to the Scientific Advisory Board of mCureX Therapeutics, a subsidiary of OliX specializing in mRNA vaccines and therapeutics.

Dr. Hartmann is a leading authority on nucleic acid therapeutics and immunology with over 20 years of experience. Most recently, he served as Director of the Institute of Clinical Chemistry and Clinical Pharmacology with Central Laboratory at the University Hospital of Bonn in Germany. He was previously Professor and Head of the Clinical Chemistry and Clinical Pharmacology Research Center at the University Hospital of Bonn. Dr. Hartmann also served as President of the Oligonucleotide Therapeutics Society (OTS), a leading global society dedicated to advancing research and development of oligonucleotides therapeutics, and Research Director at the University Hospital of Bonn. In 2014, Dr. Hartmann founded Rigontec GmbH, an RNA-based immunotherapy development company, acquired by Merck in 2017.

“We are pleased to welcome Dr. Hartmann to our Scientific Advisory Board. Dr. Hartmann brings deep expertise and know-how in the research and development of nucleic acid therapeutics and the field of immunology more broadly and we are pleased to work with him to accelerate the research and development of our pipeline of mRNA vaccines and therapeutics,” said Sun Woo Hong, Ph.D., chief executive officer of mCureX.

Dr. Hartmann received his Ph.D. from the University of Ulm in Germany, completing postdoct acid therapeutics, immune responses, and RNA interference technology in cancers and infectious diseases.